The use of semaglutide-based medications, including Ozempic and Wegovy, has expanded rapidly in recent years due to their effectiveness in managing type 2 diabetes and promoting weight loss. However, emerging data has led to growing concern among mental health professionals regarding potential psychiatric side effects associated with these medications. While most adverse effects linked to GLP-1 (glucagon-like peptide-1) receptor agonists are gastrointestinal, reports of mental health issues—such as anxiety, depression, and suicidal ideation—have raised questions about the safety profile of these drugs, particularly in vulnerable populations. This article explores the current evidence regarding potential mental health effects of semaglutide-based drugs, clinical concerns raised by experts, and how mental health professionals and patients can navigate these challenges with informed, evidence-based strategies.
Understanding Semaglutide and Its Applications
Semaglutide is a glucagon-like peptide-1 receptor agonist primarily prescribed for the treatment of type 2 diabetes under the brand name Ozempic. It works by stimulating insulin production, reducing glucose production in the liver, and delaying stomach emptying, which collectively helps regulate blood sugar levels. In 2021, the U.S. Food and Drug Administration (FDA) approved a higher-dose formulation of semaglutide—Wegovy—for chronic weight management in adults.
The drug’s effect on appetite and satiety is a key factor in its efficacy for weight loss. GLP-1 hormones are naturally released in the gastrointestinal tract after eating, contributing to the feeling of fullness and reduced hunger. By mimicking these hormones, semaglutide suppresses appetite and promotes weight reduction. However, its influence on the brain is not fully understood, and this has prompted further scrutiny from both medical researchers and mental health professionals.
Adverse Psychiatric Events: Evidence and Concerns
Public health researchers Hajer Elkout and pharmacologist Mansour Tobaiqy have observed a correlation between the increased prescription rates of semaglutide and GLP-1-based drugs and a rise in reported adverse psychiatric events. Although these events account for only 1.2 percent of total adverse effect reports for these medications, researchers have confirmed that 20 reported cases had fatal or life-threatening outcomes. The European database of drug side effects relies on self-reported data, which limits the ability to establish a causal relationship between these psychiatric events and the medication itself.
In 2023, the European Medicines Agency issued a statement expressing concern over Ozempic due to reports of suicidal thoughts, ideations, and self-injurious behaviors. Similarly, the United Kingdom has also raised concerns. However, findings from the U.S. National Institute of Health suggest that individuals using GLP-1-based medications show a reduced risk of suicidal ideation compared to those using other anti-obesity drugs. The FDA has been investigating the mental health effects of GLP-1s but has not found conclusive evidence of causation to date.
This divergence in findings highlights the need for further research into the potential psychiatric risks of GLP-1-based drugs. Despite the apparent lack of causal links, the sheer seriousness of these adverse events necessitates a precautionary approach from healthcare professionals and patients alike.
Differential Labeling and Clinical Implications
One point of confusion for patients and practitioners stems from the difference in drug labeling between Ozempic and Wegovy. While the active ingredient in both medications is semaglutide, Wegovy’s label includes warnings about potential mental health side effects such as anxiety, depression, and suicidal ideation. Ozempic’s label does not include these similar warnings. According to Dr. Sethu Reddy, president of the American Association of Clinical Endocrinology, this discrepancy does not mean the drug manufacturer or the FDA is concealing information. Rather, it reflects the nature of how adverse events are documented and reported during clinical trials.
Dr. Raafat Girgis explains that during the FDA approval process, drug companies must report adverse events that occur more frequently in patients receiving the medication than in the placebo group. Mental health side effects, particularly for drugs like Ozempic, often go undetected during smaller-scale trials and emerge only after widespread use increases the number of reported cases. As a result, previously unidentified side effects may be added to product labels as awareness and documentation grow.
For patients and caregivers, this suggests that being aware of the potential mental health risks of GLP-1 medications is vital—even if a specific drug has not yet included such warnings in its labeling. Dr. Girgis emphasizes that if any changes in mental health occur while using a GLP-1 drug, individuals should contact their healthcare provider.
Mechanisms and Potential Psychological Effects
The precise mechanism through which semaglutide may impact mental health is not yet fully understood. However, experts like Dr. Reddy suggest that appetite suppression, an intended effect of the drug, may inadvertently influence brain chemistry and emotional regulation. The hypothalamus, which plays a central role in regulating hunger and satiety, is also linked to emotional responses and stress management. Changes in appetite-related signaling may, therefore, have broader consequences on mood and mental well-being.
Additionally, the gastrointestinal effects of semaglutide—nausea, vomiting, and delayed digestion—are known to be some of the most common side effects reported by users. These effects can lead to discomfort, dissatisfaction, or even avoidance of food, which may disrupt natural eating patterns and potentially trigger emotional distress. In this way, both the intended and unintended effects of the drug may indirectly influence mental health in ways that warrant closer attention from both prescribers and consumers.
Patient Reports and Anecdotal Concerns
Anecdotal reports suggest that some patients have experienced significant changes in mental health while using semaglutide-based drugs. These reports range from mild emotional disturbances to severe symptoms such as suicidal ideation. While anecdotal data is not sufficient to establish causation, it does provide valuable insight into the lived experiences of patients and can guide further clinical investigation.
For example, some users have reported increased anxiety and depression symptoms following the initiation of Ozempic or Wegovy, even in the absence of pre-existing mental health conditions. These effects may be exacerbated in patients with a history of mood disorders or those already at risk for emotional dysregulation. It also contributes to a broader concern among mental health professionals about the potential long-term mental health implications of these drugs.
Dr. Girgis notes that while adverse psychiatric events are rare, their severity means that any potential connection with GLP-1 medications should be taken seriously. Patients are encouraged to maintain open communication with their healthcare providers and to report any changes in mood or emotional well-being, even if they seem minor.
Broader Health Concerns with GLP-1 Medications
In addition to mental health, there are other emerging concerns regarding the long-term safety of GLP-1 medications. For example, there have been reports linking the use of GLP-1 drugs with vision impairment or rare eye conditions, as discussed in a study published in 2024. An observational study found a higher incidence of a rare eye condition among individuals taking semaglutide than in the general population, but it did not prove a direct causal relationship.
Public figures such as singer Robbie Williams have also reported experiencing vision changes they attribute to these medications, raising awareness about their potential wider health impacts. Whether these broader health concerns are linked to mental health complications remains an open area of research. In any case, the interconnectedness of physical and mental health underscores the value of a holistic approach to monitoring and treating patients on GLP-1 medications.
The Role of Mental Health Professionals in Monitoring Patients
Given the potential risks associated with GLP-1 medications, mental health professionals play a critical role in ensuring the well-being of patients undergoing treatment with these drugs. Even in the absence of clear causal data, the possible influence of GLP-1 medications on mental health warrants close attention from mental health practitioners.
Therapists and clinicians should be aware of the reported side effects and consider possible psychiatric or emotional consequences in patients who present with changes in mood, anxiety, or appetite following semaglutide treatment. Open dialogues between patients and mental health professionals are essential in identifying early warning signs and providing appropriate support, whether through therapeutic interventions or referrals to their primary care physicians.
Additionally, given the potential link between GLP-1 medications and eating behaviors, mental health professionals working in areas such as eating disorder treatment, weight management, and anxiety conditions should be particularly vigilant. Clients undergoing weight loss or diabetes management with these drugs may require specialized care and regular mental health assessments to prevent or address complications.
Clinical and Regulatory Oversight
Regulatory and public safety organizations are continuously evaluating the safety and efficacy of GLP-1 medications in light of new reports and studies. Both the FDA and the European Medicines Agency remain engaged in monitoring mental health outcomes and adverse effects associated with these drugs. Additionally, clinical guidelines and recommendations for prescribing GLP-1s are likely to evolve as more data becomes available.
Researchers are also conducting retrospective and prospective studies to assess the long-term psychiatric effects of GLP-1 medications, particularly in high-risk populations such as individuals with a history of mental health disorders or substance use. At the same time, health organizations and professional guidelines are emphasizing the importance of thorough patient screening and monitoring before and during semaglutide treatment. This includes evaluating a patient’s mental health history, current symptoms, and potential risk factors before initiating therapy and maintaining regular check-ins throughout the treatment process.
Conclusion
Semaglutide-based medications such as Ozempic and Wegovy offer valuable treatment options for managing type 2 diabetes and promoting weight loss. However, emerging evidence and patient reports suggest that these drugs may be associated with potential psychiatric side effects, including anxiety, depression, and suicidal ideation. While the data does not yet establish a clear causal link between semaglutide and mental health outcomes, the seriousness of these symptoms demands a cautious and informed approach from both healthcare providers and patients.
Given the current limitations in clinical data, mental health professionals and patients should remain vigilant for any changes in emotional well-being during GLP-1 treatment. Ongoing research is critical to fully understanding the potential mental health risks of these medications, particularly in the long-term. Until more definitive evidence is available, close collaboration between prescribers and patients—and regular mental health assessments—can help mitigate risks and support optimal use of these life-changing drugs.